Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with invasive breast cancer confirmed through a laboratory tissue test.
- People whose cancer is hormone receptor-positive (meaning the cancer cells respond to the hormones oestrogen and/or progesterone) and HER2-negative (a specific protein is not overactive on the cancer cells), based on specific test measurements (confirm with trial site for exact values).
- People whose breast cancer has spread, come back, or cannot be removed by surgery (also called advanced, recurrent, or Stage IV breast cancer).
- People aged 18 or older at the time of registration.
- People who are generally well enough to carry out daily activities, as measured by a standard medical scale called the ECOG Performance Status of 0 or 1 — roughly meaning fully active or able to do light activity (confirm with trial site).
Who may not be able to join:
- People whose cancer has spread to internal organs and is causing symptoms, or for whom hormone-based treatment has been judged unsuitable by their doctor.
- People who have previously received hormone therapy or chemotherapy specifically for advanced or recurrent breast cancer.
- People who have previously taken a type of cancer medicine called a CDK4/6 inhibitor, either before or after surgery, or for advanced disease.
- People who have taken hormone-based therapy after surgery within the 35 days before the study start date.
- People who have another active cancer diagnosis, with some exceptions such as certain skin cancers that have been removed, or other cancers where the person has been cancer-free for five or more years (confirm with trial site for full list of exceptions).
- People who have had a serious allergic reaction to ribociclib, anastrozole, or any ingredients in these medicines, including those with soy or peanut allergies, or certain sugar intolerances.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hiroji Iwata, MD. PhD., Nagoya City University
Phone: +81-52-853-8020
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase 1b part: Dose Limiting Toxicity; Phase 2 part: Overall response rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.